Molecular profiling of melanoma tumours explains differences in survival after T cell therapy
Published 28 November 2017 Göran Jönsson (Photo: Tove Smeds) The more times metastasised melanoma has mutated and the patient’s immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration between Lund University in Sweden and Herlev university hospital in Denmark. The findings are now published in